April 4, 2017 / 10:22 AM / 5 months ago

BRIEF-Redhill Biopharma receives FDA orphan drug designation for cholangiocarcinoma drug

April 4 (Reuters) - Redhill Biopharma Ltd:

* Redhill Biopharma receives fda orphan drug designation for yeliva® for the treatment of cholangiocarcinoma

* Redhill Biopharma Ltd says a phase i study with yeliva in patients with advanced solid tumors successfully met its primary and secondary endpoints

* Redhill Biopharma -phase iia clinical study with yeliva in patients with advanced, unresectable, intrahepatic and extrahepatic cholangiocarcinoma planned in Q3

* Redhill Biopharma -to initiate phase iia clinical study with yeliva in patients with advanced,unresectable,intrahepatic,extrahepatic cholangiocarcinoma in Q3

* Redhill Biopharma -phase ii study to evaluate efficacy of yeliva in patients with moderate to severe ulcerative colitis is to be initiated in h2 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below